Loading organizations...
Loading organizations...
Raze Therapeutics is a technology company.
My research indicates that "Raze Therapeutics" primarily refers to a non-profit organization offering health and therapy services, such as physical and occupational therapy, based on available web search results. Attempts to fetch content from their official website were unsuccessful due to a "Too Many Requests" error.
Further targeted searches for "Raze Therapeutics" in the context of biotech or drug discovery yielded no relevant results. This suggests that there is no prominent company by this exact name operating in the drug development sector that would typically be the focus for a venture capital audience.
Therefore, I am unable to generate a company profile for a VC audience about a drug discovery or biotech firm named "Raze Therapeutics," as no such entity aligning with that profile could be identified through thorough web research. The information found pertains to a service-oriented non-profit, which does not fit the typical investment criteria for venture capitalists in the therapeutics space.
Raze Therapeutics has raised $24.0M across 1 funding round.
Raze Therapeutics has raised $24.0M in total across 1 funding round.
Raze Therapeutics has raised $24.0M in total across 1 funding round.
Raze Therapeutics's investors include ARCH Venture Partners, Atlas Venture, Hatteras Venture Partners, MPM Capital, M Ventures (Merck), Omega Funds, RA Capital, Roche Venture Fund, SV Health Investors, Astellas Venture Management, Nilesh Kumar, Novartis.
Raze Therapeutics is a biotechnology company focused on discovering and developing a new class of oncology therapeutics that target fundamental metabolic pathways essential to tumor biology, such as proliferation, survival, and biomass accumulation.[1][4] It serves cancer patients and the medical community by addressing unmet needs in tumor metabolism, with a drug pipeline, patents, clinical trials, and a technology platform in oncology.[2] The company launched with strong early momentum, securing $24 million in Series A financing to advance its innovative approach.[4]
Note: A separate non-profit entity named Raze Therapeutics provides in-home psychiatric therapy and medication management services, but it operates distinctly from the biotech firm and lacks investor or tech ecosystem ties.[3]
Raze Therapeutics emerged as a biotech startup dedicated to oncology innovation, launching publicly with a $24 million Series A financing round to fuel its metabolic pathway targeting efforts.[4] While specific founders and exact founding year are not detailed in available sources, the company's inception aligns with advances in tumor biology research, positioning it to pioneer anabolic pathway inhibitors.[1][4] Early traction is evident from its immediate funding success and development of a drug pipeline with associated patents and clinical trials.[2]
Raze Therapeutics rides the wave of precision oncology and metabolic reprogramming trends, where therapies exploit tumor-specific vulnerabilities like anabolic dependencies amid rising cancer incidence and resistance to existing treatments.[1][4] Timing is favorable due to maturing tools in pathway mapping and CRISPR-enabled discovery, amplified by market forces like surging biotech investment in immuno-oncology alternatives.[4] It contributes to the ecosystem by advancing fundamental tumor biology insights, potentially influencing pipeline development across pharma peers targeting similar metabolic nodes.[2]
Raze is poised to advance its oncology pipeline toward clinical milestones, with pipeline expansion, trial readouts, and potential partnerships shaping near-term progress.[2][4] Trends like AI-driven drug design and combination therapies with immunotherapies will likely accelerate its metabolic targeting efforts, evolving its role from early-stage innovator to key player in next-gen cancer care. This positions Raze to redefine oncology therapeutics from its strong Series A foundation.[1][4]
Raze Therapeutics has raised $24.0M across 1 funding round. Most recently, it raised $24.0M Series A in October 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2014 | $24.0M Series A | ARCH Venture Partners, Atlas Venture, Hatteras Venture Partners, MPM Capital, M Ventures (Merck), Omega Funds, RA Capital, Roche Venture Fund, SV Health Investors, Astellas Venture Management, Nilesh Kumar, Novartis, Reza Halse |